Lalitpur pharma park: U.P. eyes one lakh crore investment, 1.5 lakh jobs

A pharma park spanning over 2,000 acres is to come up in Lalitpur, which will accommodate up to 70 manufacturing units.

The park is expected to attract an investment of Rs 1 lakh crore into the state, a press statement issued by the state government on Monday read.

This development is expected to generate more than 1.5 lakh job opportunities. Supporting industries related to pharma will indirectly create 3 lakh jobs, the release read further.

The state government will provide 94 plots in the park, in which plots will range from five acres to 50 acres. This includes three plots of 50 acres, five of 30 acres, eight of 20 acres, 15 plots of 15 acres, 20 plots of 10 acres, and 43 plots of five acres each. Out of the total area, the government will provide plots for industry set-ups in 53%, while the remaining portion will be allocated for other facilities, the statement read.

The park will also allocate 60 acres for residential (housing group) and 40 acres for commercial activities.

Ensuring smooth power supply and upgrading the airport is also in the plan. Additionally, a check-dam reservoir and a pumping station will be constructed on the Jamni River at an estimated cost of 60 crore.

Along with this, about 12 types of concessions will be given to the industry to set up plants in UP. These include interest subsidy, SGST refund, exemption from stamp duty and registration charges, electric duty exemption, EPF reimbursement, hire subsidy, air cargo handling subsidy, patent registration subsidy, quality certification subsidy, skill development incentive, and others.

Related Posts

  • Pharma
  • May 16, 2025
  • 47 views
Emcutix and Mantra Pharma Introduce Ureaderm: Advanced Urea-Based Moisturizers for Indian Skin

Emcutix Biopharmaceuticals Ltd in partnership with Canada-based Mantra Pharma Inc—both subsidiaries of Emcure Pharmaceuticals Ltd—has launched Ureaderm 10% and 20%, a new range of urea-based moisturizers designed to address severe dryness…

  • Pharma
  • May 16, 2025
  • 69 views
DCA seizes syrup stocks over misleading fever cure claim

Officials from the Telangana Drugs Control Administration (DCA) have seized stocks of a syrup marketed as a cure for ‘all types of fevers’, citing violation of the Drugs and Magic…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Emcutix and Mantra Pharma Introduce Ureaderm: Advanced Urea-Based Moisturizers for Indian Skin

Emcutix and Mantra Pharma Introduce Ureaderm: Advanced Urea-Based Moisturizers for Indian Skin

DCA seizes syrup stocks over misleading fever cure claim

DCA seizes syrup stocks over misleading fever cure claim

Mankind Pharma Faces Rs 341.86 Cr Tax Demand

Mankind Pharma Faces Rs 341.86 Cr Tax Demand

Piramal Pharma stock falls 5% after Q4 results; check key numbers here

Piramal Pharma stock falls 5% after Q4 results; check key numbers here

Biolumpivaxin: Bharat Biotech launches new vaccine against lumpy skin disease

Biolumpivaxin: Bharat Biotech launches new vaccine against lumpy skin disease

DTAB asks DCGI to take up withdrawal of license for certain FDC antibiotics with SLAs

DTAB asks DCGI to take up withdrawal of license for certain FDC antibiotics with SLAs